Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01814501 · ClinicalTrials.gov registry record · Phase 2
Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
A Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, sponsored by John Hays.
- Completed
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
- 2
- Study locations
NCT01814501: Completed Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, sponsored by John Hays.
NCT01814501 is a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer that has completed, run by John Hays. The registered enrollment target is 16 participants, below the 29-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (45% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01814501, a Phase 2 study of Recurrent Colon Cancer and Recurrent Rectal Cancer, has completed, sponsored by John Hays.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
- 2
- Study locations
Study Summary
This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, and irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving panitumumab and combination chemotherapy together may kill more tumor cells
Primary Outcome
Continuous variables will be expressed by means, standard deviations and 95% confidence intervals. Estimated using the Kaplan-Meier estimator with confidence interval calculated based on the Brookmeyer-Crowley method.
Conditions Studied
Interventions
- DRUG fluorouracil
- DRUG leucovorin calcium
- DRUG irinotecan hydrochloride
- BIOLOGICAL panitumumab
Study Locations (2)
Ohio
- Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center - Columbus
Tennessee
- Vanderbilt-Ingram Cancer Center - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2013-02-01 |
| Est. Completion | 2018-08-06 |
| Phase | Phase 2 |
What the finished NCT01814501 record still lists
NCT01814501 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 29-participant average among 10 other Recurrent Colon Cancer trials with a reported enrollment target (45% lower).
The record links to 8 conditions, with Recurrent Colon Cancer appearing as the primary indexed condition, and to 4 interventions - of which fluorouracil is the first listed.
NCT01814501 reports a single indexed study location in Ohio, Tennessee.
Frequently Asked Questions
What is clinical trial NCT01814501 about?
NCT01814501 is a clinical study titled "Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab". This phase II trial studies how well panitumumab and combination chemotherapy works in treating patients with metastatic colorectal cancer previously treated with combination chemotherapy and bevacizumab. Monoclonal antibodies, such as panitumumab, can block tumor growth in different ways. Some bloc...
What is the current status of trial NCT01814501?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2013-02-01. Estimated completion is 2018-08-06.
What conditions does trial NCT01814501 study?
This clinical trial studies the following conditions: Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Mucinous Adenocarcinoma of the Colon.
What interventions are being tested in trial NCT01814501?
The interventions under investigation include: fluorouracil (DRUG), leucovorin calcium (DRUG), irinotecan hydrochloride (DRUG), panitumumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT01814501?
This trial is sponsored by John Hays, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01814501 being conducted?
This trial has 2 study locations across Ohio, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01814501's enrollment target sits among peer trials
16 7th of 10 higher than 3 of 10 other Recurrent Colon Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Colon Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
2 Phase Comparison of Pre-operative CT and PET Images for Metastatic Colorectal Cancer
COMPLETED · Phase 2
-
Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
COMPLETED · Phase 1
-
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
COMPLETED · Phase 1
-
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI